Cstone Pharmaceuticals Co. Ltd. presented preclinical data of CS-2009, a trispecific antibody targeting PD-1, CTLA-4 and VEGF-A, for cancer immunotherapy.
At the annual meeting of the American Society for Human Genetics, scientists presented three new cases of Kabuki syndrome presented with developmental delay, autism and myopia as the common traits.
Gain-of-function mutations and overexpression of the EZH2 gene lead to H3K27Me3 accumulation, which in turn initiates tumorigenesis and tumor progression, thus making it a promising target for therapy.
Activin receptor-like kinase 5 (ALK5) is a member of the transforming growth factor-β (TGF-β) family associated with tumor development and progression that impacts cancer immune response within the tumor microenvironment.
Primary aldosteronism (PA), caused by bilateral adrenal hyperplasia or aldosteronomas, is the leading cause of endocrine hypertension, with an estimated prevalence of 10%-20% in patients in tertiary hospitals.
Investigators from New York State Office for People with Developmental Disabilities (OPWDD) and affiliated organizations have reported the discovery and preclinical characterization of a gene therapy as well as a new animal model for Ogden syndrome.
Researchers from Canwell Biotech Ltd. presented preclinical data for CAN-2109, a novel long-acting immunogenic cell death inducer being developed for the treatment of cancer.
Astellas Pharma Inc. presented the first preclinical data on ASP-1002, a bispecific antibody targeting claudin-4 (CLDN4) and CD137, for the treatment of patients with metastatic or locally advanced solid tumors.
Complex genomic rearrangements (CGRs) involve large-scale genomic alterations with multiple breakpoints and are implicated in genetic diseases such as malformation syndromes, intellectual disability and neurodevelopmental disorders.
RSS
